The global market is expected to grow at an approximate CAGR of 7.5% by 2023

Pericarditis is a cardiovascular disease in which pericardium sac swells. The symptoms of the disease are inclusive of the chest pain, heart palpitations, and others. This medical condition can be acute, chronic or recurrent. However, it is estimated that most of the reported cases are for acute pericarditis. The growing geriatric population is at a higher susceptibility for the development of the pericarditis. Thus, the growing geriatric population is one of the major drivers for the market. According to the World Health Organization, the geriatric population of the U.S. is expected reach 98 million by 2060. Such an increase in the growing geriatric population will boost the market growth. Moreover, increasing healthcare expenditures and rising prevalence of the cardiovascular diseases fuels the market growth. According to the Centres for Disease Control and Prevention, in 2015, the U.S. total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. However, the market will be restricted by the lack of awareness and low per capita healthcare expenditure within the developing economies during the forecast period.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1847 .

Segmentation

The global pericarditis market is segmented on the basis of type, diagnosis, treatment, and end users.

On the basis of type, the market is segmented into acute, chronic, recurrent pericarditis, and others.

On the basis of diagnosis, the market is segmented into electrocardiogram, echocardiogram, X-ray blood test, and others. The electrocardiogram segment, is sub segmented into EKG, ECG, and others. The echocardiogram segment is sub segmented into transthoracic echocardiogram, transesophageal echocardiogram, stress echocardiogram, and others.

On the basis of treatment, the market is segmented into pharmacologic, surgical, and others. The pharmacologic segment is further segmented into non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and others. The NSAIDs segment is sub segmented into aspirin, ibuprofen, and others. The surgical segment is sub-segmented into pericardiectomy, pericardiocentesis, pericardiotomy, and others.

On the basis of end users, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Regional Analysis

America dominates the global pericarditis market owing to rising healthcare expenditure, huge patient population for the cardiovascular diseases and growing geriatric population. Moreover, the region is marked by the presence of developed economies like the U.S. and Canada which are technologically advanced and have a well-developed healthcare expenditure. This, additionally, fuels the market growth during the forecast period.

Europe is the second largest pericarditis market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, increasing healthcare expenditures drives the market growth within the region. Moreover, favorable government policies and increasing funds for research fuels the market growth.

Asia Pacific is the fastest growing region due to increasing demands for the healthcare services followed by growing geriatric population and rising healthcare expenditures fuels the market. Moreover, the region have huge opportunities for the development of the market due the presence of the developed economies like India and China.

The Middle East & Africa holds the least share of the market owing to the presence of poor economies especially, in African region. Moreover, stringent government policies within the region, restrains the market growth. A majority of the market within this region is held by the Middle East due to the well-developed healthcare sector and huge healthcare expenditure.

Key Players

The key players for the global pericarditis market are Pfizer Inc. (U.S.), AstraZeneca (U.S.), Bayer AG (Europe), Reckitt Benckiser Group plc. (Europe), PerkinElmer, Inc. (U.S.), FUJIFILM Holdings Corporation (Asia Pacific), Merck Sharp & Dohme Corp. (U.S.), ALLERGAN (Europe), and others.

Browse Complete Report at https://www.marketresearchfuture.com/reports/pericarditis-market-1847 .

Pericarditis is a condition of swelling and irritation of the pericardium sac which may cause chest pain, heart palpitations and others. Chest pain in pericarditis occurs when the irritated layers of the pericardium rub against each other. The pericarditis is classified by type as acute, chronic and recurrent pericarditis. Acute pericarditis begins suddenly and does not last long whereas chronic pericarditis occurs when the symptoms develop more gradually and persist for long duration of weeks to months. Most of the pericarditis cases are acute and they improve on their own. However, sometimes the treatment for chronic cases may include medication and surgery. According to the studies conducted by the American Heart Association growing geriatric population is more susceptible to pericarditis. Moreover, it is estimated that 15% to 30% of the patients who have been treated for pericarditis can again develop the condition. According to the World Health Organization, geriatric population of the U.S. is expected reach 98 million by 2060. This growing geriatric population, increasing prevalence of cardiovascular diseases and rising healthcare are the main drivers for the market growth. However, lack of awareness and low per capita healthcare expenditure in the developing countries may restrain the market growth during the forecast period.

About us
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
P: +1 646 845 9312
W: www.marketresearchfuture.com
sales@marketresearchfuture.com

This release was published on openPR.